NCT03164486Active, not recruitingEarly phase 1
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- First submitted
- 22 May 2017
- Start date
- 1 Nov 2016
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Julie L. Sutcliffe, Ph.D
- Diseases
- Lung cancer, Pancreatic cancer, Colorectal cancer
- NCT number
- NCT03164486
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 27
- From 1 Nov 2016 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in another clinical trial involving an investigational agent within 4 weeks of enrollment
Lab values
- Creatinine \> 2 x upper limit of normal
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 2 x upper limit of normal
Other
- Life expectancy \< 3 months (mo)
- Women who are pregnant or breast-feeding
- Patients who cannot undergo PET/compute tomography (CT) scanning
- Lack of availability for follow-up assessments
Who the study is looking for
- Diagnosed with primary or metastatic cancer in one or more of the following locations: breast, colorectal, lung, pancreas
- Eastern Cooperative Oncology Group (ECOG) performance score of 0-1
- Will sign the Institutional Review Board (IRB)-approved consent form
- Able to remain motionless for up to 30-60 minutes per scan
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California Davis Comprehensive Cancer Center Coordinator of this site? Confirm its status | Sacramento | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.